This site is intended for
US
Healthcare Professionals only.

For Patients
 

Evolving Clinical Expectations in Immuno-Oncology

Immuno-Oncology (I-O) is a different approach that fights cancer by targeting the immune system

  • Treatment approaches currently approved to fight cancer include chemotherapy, radiation, targeted therapy, and immunotherapy
  • Each approach has unique differentiating factors
  • Cancer treatment approaches such as radiation, chemotherapy, and targeted therapy are all directed toward killing tumor cells1-4
    • Although each of these approaches has distinct mechanisms, the aim is similar: targeting tumor cells in order to fight cancer1-3
  • This underlying aim should be considered when assessing side effects, endpoints, and other aspects of cancer treatment1,5

Immune Pathways

See where our I-O research into immune pathways is heading

Learn more

I-O Biomarkers

Read about I-O biomarkers we're currently investigating

Learn more

REFERENCES–Clinical expectations

1. Ricci MS, Zong W-X. Chemotherapeutic approaches for targeting cell death pathways. Oncologist. 2006;11(4):342-357. 2. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67(19):8980-8984. 3. Joo WD, Visintin I, Mor G. Targeted cancer therapy—are the days of systemic chemotherapy numbered? Maturitas. 2013;76(4):308-314. 4. Jones TS, Holland EC. Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene. 2012;31(16):1995-2006. 5. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193-199. 6. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiation Oncol Biol Phys. 979;5(1):85-91. 7. Hoos A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235-247.